Clinical Trials Using Gemtuzumab Ozogamicin

Clinical trials are research studies that involve people. The clinical trials on this list are studying Gemtuzumab Ozogamicin. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 1-4 of 4
  • OX40, Utomilumab, Avelumab, Glasdegib, Gemtuzumab Ozogamicin, and Azacitidine in Treating Participants with Relapsed or Refractory Acute Myeloid Leukemia

    This phase IB / II trial studies the side effects and best dose of anti-OX40 antibody PF-04518600 (OX40) and how well it works alone or in combination with utomilumab, avelumab, glasdegib, gemtuzumab ozogamicin, and azacitidine in treating participants with acute myeloid leukemia that has come back or does not respond to treatment. Monoclonal antibodies, such as OX40, utomilumab, avelumab, and gemtuzumab ozogamicin, may interfere with the ability of cancer cells to grow and spread. Glasdegib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as azacitidine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving OX40, utomilumab, avelumab, glasdegib, gemtuzumab ozogamicin, and azacitidine may work better in treating participants with acute myeloid leukemia.
    Location: M D Anderson Cancer Center, Houston, Texas

  • Tretinoin and Arsenic Trioxide with or without Gemtuzumab Ozogamicin in Treating Patients with Previously Untreated Acute Promyelocytic Leukemia

    This phase II trial studies how well tretinoin and arsenic trioxide with or without gemtuzumab ozogamicin works in treating patients with previously untreated acute promyelocytic leukemia. Drugs used in chemotherapy, such as tretinoin and arsenic trioxide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotoxins, such as gemtuzumab ozogamicin, may find certain cancer cells and kill them without harming normal cells. Giving tretinoin and arsenic trioxide together with gemtuzumab ozogamicin may kill more cancer cells.
    Location: 5 locations

  • Gemtuzumab Ozogamicin with G-CSF, Cladribine, Cytarabine and Mitoxantrone in Treating Participants with Previously Untreated Acute Myeloid Leukemia or High-Grade Myeloid Neoplasm

    This phase I / II trial studies the side effects and best dosing frequency of gemtuzumab ozogamicin when given in combination with granulocyte colony stimulating factor (G-CSF), cladribine, cytarabine and mitoxantrone (GCLAM) and to see how well they work in treating participants with acute myeloid leukemia or high-grade myeloid tumors (neoplasms) that have not been previously treated. Antibody-drug conjugates, such as gemtuzumab ozogamicin, act by directly delivering toxic chemotherapy to cancer cells. Granulocyte colony stimulating factor is a growth factor used to stimulate leukemia cells and render them more sensitive to chemotherapy drugs. Drugs used in chemotherapy, such as cladribine, cytarabine and mitoxantrone, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving gemtuzumab ozogamicin in combination with G-CSF, cladribine, cytarabine and mitoxantrone hydrochloride may work better in treating participants with acute myeloid leukemia or high-grade myeloid neoplasm.
    Location: Fred Hutch / University of Washington Cancer Consortium, Seattle, Washington

  • Gemtuzumab Ozogamicin in Treating Patients with Relapsed or Refractory Acute Myeloid Leukemia, Acute Promyelocytic Leukemia, or Chronic Myelogenous Leukemia

    This clinical trial studies gemtuzumab ozogamicin in treating patients with relapsed or refractory acute myeloid leukemia, acute promyelocytic leukemia, or chronic myelogenous leukemia. Monoclonal antibodies, such as gemtuzumab ozogamicin, can block cancer growth in different ways. Some block the ability of cancer to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them.
    Location: Comprehensive Cancer Center of Wake Forest University, Winston-Salem, North Carolina